First Wave BioPharma Inc. shares were up 16% to $3.26 one day after the company said the U.S. Food and Drug Administration reviewed its Investigational New Drug application and provided a "Study May Proceed" letter for a Phase 2a trial.
The trial is investigating FW-ICI-AC as a treatment for Grade 1 and Grade 2 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors.
FW-ICI-AC is a proprietary oral immediate-release tablet formulation of niclosamide, a prescription small molecule with anti-inflammatory and anti-viral properties.
The company said the Phase 2a clinical trial is designed to determine the safety, tolerability, and preliminary efficacy of FW-ICI-AC in the treatment of immune checkpoint inhibitor-associated colitis and diarrhea in advanced cancer patients. About 60 patients will be enrolled in the trial and divided into two arms.
One arm will receive FW-ICI-AC three times daily for two weeks, while the other arm will receive placebo three times daily for two weeks. Following treatment, each patient will enter a four-week evaluation period. The primary endpoint of the trial is safety and tolerability of FW-ICI-AC. Additional endpoints will measure early signals of efficacy, including resolution of the patient's diarrhea, sparing of steroids, and prevention of disease progression.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.